Multiple sclerosis market to generate sales of $29.8 bn by 2030: GlobalData
Tolebrutinib is expected to be the leading BTK inhibitor by 2030, with forecasted sales of approximately $2.6B across the 7MM
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
BTK inhibitors
Sanofi to acquire Principia Biopharma
The deal adds to Sanofi’s R&D areas of autoimmune and allergic diseases